{"id":"https://openalex.org/W1127933869","doi":"https://doi.org/10.1097/cji.0000000000000089","title":"Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents","display_name":"Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents","publication_year":2015,"publication_date":"2015-08-11","ids":{"openalex":"https://openalex.org/W1127933869","doi":"https://doi.org/10.1097/cji.0000000000000089","mag":"1127933869","pmid":"https://pubmed.ncbi.nlm.nih.gov/26261889"},"language":"en","primary_location":{"id":"doi:10.1097/cji.0000000000000089","doi":"https://doi.org/10.1097/cji.0000000000000089","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cji.0000000000000089","pdf_url":null,"source":{"id":"https://openalex.org/S177451610","display_name":"Journal of Immunotherapy","issn_l":"1524-9557","issn":["1524-9557","1537-4513"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Immunotherapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103199998","display_name":"George Dranitsaris","orcid":"https://orcid.org/0000-0002-2943-7770","observed_orcids":["https://orcid.org/0000-0002-2943-7770"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]},{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]},{"id":"https://openalex.org/I4210158068","display_name":"Heat Biologics (United States)","ror":"https://ror.org/05p6m4w34","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158068"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["CA","GB","US"],"is_corresponding":true,"raw_author_name":"George Dranitsaris","raw_affiliation_strings":["*Heat Biologics Inc., Durham, NC \u2020Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA \u2021Drug Development Office, Cancer Research UK, London, UK \u00a7Division of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada \u2225Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL","University of Miami, Coral Gables, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"*Heat Biologics Inc., Durham, NC \u2020Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA \u2021Drug Development Office, Cancer Research UK, London, UK \u00a7Division of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada \u2225Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL","institution_ids":["https://openalex.org/I145608581","https://openalex.org/I2801316944","https://openalex.org/I2802654988","https://openalex.org/I4210158068","https://openalex.org/I79576946"]},{"raw_affiliation_string":"University of Miami, Coral Gables, United States","institution_ids":["https://openalex.org/I145608581"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110382646","display_name":"Roger B. Cohen","orcid":"https://orcid.org/0009-0004-7423-2653","observed_orcids":["https://orcid.org/0009-0004-7423-2653"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roger B. Cohen","raw_affiliation_strings":["Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA","#N#               * University of Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA","institution_ids":["https://openalex.org/I79576946"]},{"raw_affiliation_string":"#N#               * University of Pennsylvania","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027866282","display_name":"Gary D Acton","orcid":"https://orcid.org/0000-0002-3285-4022","observed_orcids":["https://orcid.org/0000-0002-3285-4022"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gary Acton","raw_affiliation_strings":["Drug Development Office, Cancer Research UK, London, UK","Cancer Research UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Development Office, Cancer Research UK, London, UK","institution_ids":["https://openalex.org/I2801316944"]},{"raw_affiliation_string":"Cancer Research UK","institution_ids":["https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069041286","display_name":"Llew Keltner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Llew Keltner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075370349","display_name":"Melissa Leigh Price","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158068","display_name":"Heat Biologics (United States)","ror":"https://ror.org/05p6m4w34","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158068"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Price","raw_affiliation_strings":["Heat Biologics Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Heat Biologics Inc","institution_ids":["https://openalex.org/I4210158068"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102844847","display_name":"Eitan Amir","orcid":"https://orcid.org/0000-0002-3706-525X","observed_orcids":["https://orcid.org/0000-0002-3706-525X"]},"institutions":[{"id":"https://openalex.org/I1325899441","display_name":"University Health Network","ror":"https://ror.org/042xt5161","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Eitan Amir","raw_affiliation_strings":["University health network;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University health network;","institution_ids":["https://openalex.org/I1325899441"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111612259","display_name":"Eckhard R. Podack","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eckhard R. Podack","raw_affiliation_strings":["Microbiology & Immunology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Microbiology & Immunology","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001670202","display_name":"Taylor Houghton Schreiber","orcid":"https://orcid.org/0000-0002-8070-1303","observed_orcids":["https://orcid.org/0000-0002-8070-1303"]},"institutions":[{"id":"https://openalex.org/I4210158068","display_name":"Heat Biologics (United States)","ror":"https://ror.org/05p6m4w34","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158068"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Taylor H. Schreiber","raw_affiliation_strings":["Heat Biologics Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Heat Biologics Inc","institution_ids":["https://openalex.org/I4210158068"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5103199998"],"corresponding_institution_ids":["https://openalex.org/I145608581","https://openalex.org/I2801316944","https://openalex.org/I2802654988","https://openalex.org/I4210158068","https://openalex.org/I79576946"],"apc_list":null,"apc_paid":null,"fwci":1.9591,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.903107,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"38","issue":"7","first_page":"259","last_page":"266"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.8838000297546387,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.8838000297546387,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.11379999667406082,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.7049999833106995},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.7400000095367432},{"id":"https://openalex.org/keywords/clinical-trial-design","display_name":"clinical trial design","score":0.972000002861023},{"id":"https://openalex.org/keywords/objective-response","display_name":"objective response","score":0.6269999742507935},{"id":"https://openalex.org/keywords/sustained-remission","display_name":"sustained remission","score":0.8080000281333923},{"id":"https://openalex.org/keywords/cd8-t-cell-priming","display_name":"CD8+ T cell priming","score":0.7829999923706055},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.746999979019165},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.597000002861023},{"id":"https://openalex.org/keywords/phase-ii-trial-design","display_name":"phase II trial design","score":0.5299999713897705},{"id":"https://openalex.org/keywords/phase-iii-trial-design","display_name":"phase III trial design","score":0.4790000021457672},{"id":"https://openalex.org/keywords/metastatic-disease","display_name":"metastatic disease","score":0.42399999499320984},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.34599998593330383}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7812584638595581},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.7565290927886963},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5321694016456604},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.5077934861183167},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.49285244941711426},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4807533919811249},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.46684202551841736},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4632801413536072},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4595974087715149},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41293489933013916},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2696085572242737}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D012107","descriptor_name":"Research Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/cji.0000000000000089","doi":"https://doi.org/10.1097/cji.0000000000000089","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cji.0000000000000089","pdf_url":null,"source":{"id":"https://openalex.org/S177451610","display_name":"Journal of Immunotherapy","issn_l":"1524-9557","issn":["1524-9557","1537-4513"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Immunotherapy","raw_type":"journal-article"},{"id":"pmid:26261889","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26261889","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of immunotherapy (Hagerstown, Md. : 1997)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8371999859809875,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":13,"referenced_works":["https://openalex.org/W1530028652","https://openalex.org/W1967835984","https://openalex.org/W1970563897","https://openalex.org/W1995452486","https://openalex.org/W2041432211","https://openalex.org/W2056898354","https://openalex.org/W2062567955","https://openalex.org/W2106461837","https://openalex.org/W2113132543","https://openalex.org/W2143512985","https://openalex.org/W2151981428","https://openalex.org/W2158679766","https://openalex.org/W2163983995"],"related_works":["https://openalex.org/W2888735178","https://openalex.org/W2766372223","https://openalex.org/W2954600065","https://openalex.org/W2470626884","https://openalex.org/W4386912950","https://openalex.org/W2753127471","https://openalex.org/W2913898163","https://openalex.org/W2751649617","https://openalex.org/W2196243720","https://openalex.org/W1995452486"],"abstract_inverted_index":{"The":[0,56],"classical":[1],"model":[2],"for":[3,138],"identification":[4],"and":[5,36,75,101,135,197],"clinical":[6,67,163,177,192],"development":[7,164],"of":[8,26,50,77,113,130,159,191],"anticancer":[9],"agents":[10],"was":[11,69],"based":[12,71],"on":[13,72],"small":[14,24],"molecules,":[15],"which":[16],"were":[17],"often":[18],"quite":[19],"toxic.":[20],"Early":[21],"studies":[22],"in":[23,52,128,144,162,176,200],"groups":[25],"patients":[27,147],"would":[28,43],"seek":[29],"to":[30,58,93,168],"identify":[31],"a":[32,47,106,111],"maximum":[33],"tolerated":[34],"dose":[35],"major":[37],"dose-limiting":[38],"toxicities.":[39],"Tumor":[40],"response":[41],"(shrinkage)":[42],"be":[44,125],"assessed":[45],"after":[46],"minimum":[48],"number":[49,112,190],"doses":[51],"phase":[53,65],"II":[54],"testing.":[55],"decision":[57],"take":[59],"the":[60,63,73,136,156,169,187],"drug":[61],"into":[62],"randomized":[64],"III":[66],"setting":[68],"usually":[70],"proportion":[74],"duration":[76],"objective":[78],"tumor":[79],"responses,":[80],"along":[81],"with":[82,86,148,165,173,194],"overall":[83],"survival":[84],"compared":[85],"historical":[87],"controls.":[88],"Immune-oncologics":[89],"that":[90,123],"are":[91],"designed":[92],"fight":[94],"cancer":[95],"by":[96,104],"direct":[97],"CD8(+)":[98],"T-cell":[99],"priming":[100],"activation":[102],"or":[103],"blocking":[105],"negative":[107],"regulatory":[108],"molecule":[109],"have":[110],"sharp":[114],"distinctions":[115],"from":[116,132],"cytotoxic":[117],"drugs.":[118],"These":[119],"include":[120],"cytoreductive":[121],"effects":[122],"may":[124],"very":[126],"different":[127,157],"timing":[129],"onset":[131],"traditional":[133],"chemotherapy":[134],"potential":[137],"inducing":[139],"long-term":[140],"durable":[141],"remissions":[142],"even":[143],"heavily":[145],"pretreated":[146],"metastatic":[149],"disease.":[150],"In":[151],"this":[152],"paper":[153],"we":[154],"review":[155],"classes":[158],"immune-oncologic":[160],"drugs":[161],"particular":[166],"attention":[167],"biostatistical":[170],"challenges":[171],"associated":[172],"evaluating":[174],"efficacy":[175],"trials.":[178],"Confronting":[179],"these":[180],"issues":[181],"upfront":[182],"is":[183],"particularly":[184],"important":[185],"given":[186],"rapidly":[188],"expanding":[189],"trials":[193,199],"both":[195],"monotherapy":[196],"combination":[198],"immunooncology.":[201]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}